MCID: ACT073
MIFTS: 58

Acute Leukemia

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Acute Leukemia

MalaCards integrated aliases for Acute Leukemia:

Name: Acute Leukemia 12 29 54 15 37 17 71
Acute Undifferentiated Leukemia 71
Undifferentiated Leukemia 71
Stem Cell Leukaemia 12
Stem Cell Leukemia 12
Acute Leukemias 15

Classifications:



External Ids:

Disease Ontology 12 DOID:12603
ICD9CM 34 208.0
NCIt 49 C9300
SNOMED-CT 67 24072005 91855006
ICD10 32 C95.00
UMLS 71 C0085669 C0280141 C1378511

Summaries for Acute Leukemia

Disease Ontology : 12 A lymphoid leukemia that occurs when a hematopoietic stem cell undergoes malignant transformation into a primitive, undifferentiated cell with abnormal longevity producing large numbers of white blood cells to be produced and enter the blood stream.

MalaCards based summary : Acute Leukemia, also known as acute undifferentiated leukemia, is related to mixed phenotype acute leukemia and acute promyelocytic leukemia. An important gene associated with Acute Leukemia is WT1 (WT1 Transcription Factor), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs Vincristine and Mercaptopurine have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Acute Leukemia

Diseases in the Leukemia family:

Chronic Leukemia Acute Leukemia
Subacute Leukemia

Diseases related to Acute Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 855)
# Related Disease Score Top Affiliating Genes
1 mixed phenotype acute leukemia 35.1 WT1 KMT2A DNTT
2 acute promyelocytic leukemia 34.0 WT1 RUNX1 KRAS KMT2A FLT3 ETV6
3 leukemia, acute myeloid 33.9 WT1 TCF3 RUNX1 PAX5 MLLT3 KRAS
4 leukemia 33.3 WT1 TCF3 STMN1 RUNX1 PAX5 MTHFR
5 childhood leukemia 33.3 TCF3 RUNX1 MTHFR MLLT3 KMT2A ETV6
6 leukemia, acute lymphoblastic 33.3 WT1 TCF3 RUNX1 PAX5 MTHFR MLLT3
7 myelodysplastic/myeloproliferative neoplasm 33.3 KMT2A KIT JAK2 FLT3 ETV6
8 lymphoblastic lymphoma 33.2 PAX5 KMT2A DNTT
9 myeloproliferative neoplasm 33.1 WT1 RUNX1 KMT2A KIT JAK2 FLT3
10 megakaryocytic leukemia 33.1 RUNX1 KMT2A JAK2
11 severe congenital neutropenia 33.0 JAK2 FLT3 CSF3
12 myelodysplastic syndrome 32.9 WT1 RUNX1 KRAS KMT2A KIT JAK2
13 precursor t-cell acute lymphoblastic leukemia 32.1 KMT2A FLT3 ETV6 DNTT
14 myeloid leukemia 32.0 WT1 RUNX1 KRAS KMT2A KIT JAK2
15 leukemia, acute lymphoblastic 3 31.9 TCF3 RUNX1 PAX5 KMT2A FLT3 ETV6
16 pancytopenia 31.7 RUNX1 KMT2A KIT FLT3 CSF3
17 monocytic leukemia 31.7 RUNX1 MLLT3 KMT2A FLT3 AFF1
18 childhood acute lymphocytic leukemia 31.7 TCF3 MTHFR ETV6 AFF1
19 down syndrome 31.6 RUNX1 MTHFR JAK2 FLT3 ETV6
20 thrombocytopenia 31.6 RUNX1 PAX5 MTHFR JAK2 ETV6 CSF3
21 t-cell acute lymphoblastic leukemia 31.6 RUNX1 KMT2A FLT3 ETV6 DNTT
22 leukemia, acute monocytic 31.5 MLLT3 KMT2A FLT3 CREBBP
23 myeloma, multiple 31.5 PAX5 KRAS KIT JAK2 FLT3 CSF3
24 acute myeloblastic leukemia with maturation 31.5 KIT FLT3
25 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 31.5 RUNX1 KMT2A KIT FLT3 ETV6 DNTT
26 leukemia, chronic myeloid 31.5 WT1 RUNX1 KRAS KMT2A KIT JAK2
27 polycythemia vera 31.4 KIT JAK2 FLT3 ETV6 CSF3
28 myelofibrosis 31.4 WT1 RUNX1 KIT JAK2 FLT3 ETV6
29 chronic leukemia 31.4 WT1 KIT JAK2 FLT3
30 myeloid sarcoma 31.4 PAX5 KMT2A KIT FLT3 DNTT
31 adult acute lymphocytic leukemia 31.3 TCF3 PAX5 MTHFR ETV6 CSF3 AFF1
32 childhood acute myeloid leukemia 31.3 WT1 KIT FLT3 BAALC
33 lymphoma, non-hodgkin, familial 31.2 PAX5 KMT2A JAK2 GSTM1 FLT3 ETV6
34 refractory anemia 31.2 RUNX1 CSF3
35 leukemia, chronic lymphocytic 31.2 PAX5 KRAS KMT2A KIT JAK2 FLT3
36 exanthem 31.2 KRAS KIT CSF3
37 essential thrombocythemia 31.2 MTHFR KRAS KIT JAK2 CSF3
38 wilms tumor 1 31.1 WT1 KRAS KMT2A KIT FLT3 CEBPA
39 chronic myelomonocytic leukemia 31.1 RUNX1 KRAS KMT2A KIT JAK2 FLT3
40 acute erythroid leukemia 31.0 JAK2 CEBPA
41 mastocytosis 30.9 KIT JAK2 FLT3
42 hematologic cancer 30.9 WT1 RUNX1 PAX5 KMT2A KIT JAK2
43 small cell carcinoma 30.8 WT1 KRAS KIT
44 cytogenetically normal acute myeloid leukemia 30.7 WT1 KMT2A FLT3 CEBPA
45 b-lymphoblastic leukemia/lymphoma 30.7 TCF3 KIT CEBPA
46 chronic eosinophilic leukemia 30.6 WT1 KIT JAK2 FLT3 ETV6
47 tetrasomy 21 30.6 RUNX1 DNTT
48 blood coagulation disease 30.6 MTHFR KIT JAK2 CSF3
49 juvenile myelomonocytic leukemia 30.5 RUNX1 KRAS KMT2A JAK2 FLT3 CREBBP
50 medulloblastoma 30.5 STMN1 PAX5 KIT JAK2 CSF3 CREBBP

Comorbidity relations with Acute Leukemia via Phenotypic Disease Network (PDN):


Deficiency Anemia Neutropenia

Graphical network of the top 20 diseases related to Acute Leukemia:



Diseases related to Acute Leukemia

Symptoms & Phenotypes for Acute Leukemia

GenomeRNAi Phenotypes related to Acute Leukemia according to GeneCards Suite gene sharing:

26 (show all 46)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-102 10.43 DNTT FLT3
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-11 10.43 KRAS
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10.43 KRAS
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-120 10.43 FLT3
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-121 10.43 CEBPA FLT3
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-122 10.43 CEBPA FLT3
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-123 10.43 FLT3
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.43 CEBPA FLT3 KRAS
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.43 CEBPA
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-163 10.43 FLT3
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.43 KRAS
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-168 10.43 KRAS
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-171 10.43 FLT3
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 10.43 KRAS
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-187 10.43 FLT3
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 10.43 KRAS
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-196 10.43 KRAS
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-197 10.43 DNTT
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 10.43 CEBPA
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.43 KRAS
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-23 10.43 KRAS WT1
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.43 KRAS
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 10.43 KRAS
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-35 10.43 WT1
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-43 10.43 CEBPA
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 10.43 KRAS
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-50 10.43 KRAS
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.43 KRAS
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.43 KRAS
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-85 10.43 CEBPA
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-93 10.43 KRAS
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-94 10.43 DNTT
33 Decreased viability GR00055-A-1 10.1 KRAS
34 Decreased viability GR00055-A-2 10.1 KRAS
35 Decreased viability GR00055-A-3 10.1 KRAS
36 Decreased viability GR00106-A-0 10.1 KRAS PAX5
37 Decreased viability GR00173-A 10.1 FLT3
38 Decreased viability GR00221-A-1 10.1 FLT3 KIT KRAS
39 Decreased viability GR00221-A-2 10.1 JAK2 KRAS
40 Decreased viability GR00221-A-4 10.1 FLT3
41 Decreased viability GR00249-S 10.1 GSTM1 RUNX1
42 Decreased viability GR00301-A 10.1 KIT KRAS
43 Decreased viability GR00381-A-1 10.1 AFF1 GSTM1 KRAS WT1
44 Decreased viability GR00386-A-1 10.1 CEBPA CREBBP CSF3 GSTM1 MTHFR PAX5
45 Decreased viability GR00402-S-2 10.1 KMT2A RUNX1
46 Reduced mammosphere formation GR00396-S 9.23 CEBPA CSF3 ETV6 GSTM1 KMT2A KRAS

MGI Mouse Phenotypes related to Acute Leukemia:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.44 AFF1 CEBPA CREBBP CSF3 DNTT ETV6
2 homeostasis/metabolism MP:0005376 10.43 CEBPA CREBBP DNTT ETV6 FLT3 JAK2
3 growth/size/body region MP:0005378 10.42 AFF1 CEBPA CREBBP ETV6 FLT3 JAK2
4 immune system MP:0005387 10.41 AFF1 CEBPA CREBBP CSF3 DNTT ETV6
5 cellular MP:0005384 10.35 CEBPA CREBBP ETV6 FLT3 JAK2 KIT
6 mortality/aging MP:0010768 10.33 AFF1 CEBPA CREBBP ETV6 FLT3 JAK2
7 cardiovascular system MP:0005385 10.32 CEBPA CREBBP ETV6 JAK2 KIT KMT2A
8 endocrine/exocrine gland MP:0005379 10.3 AFF1 CEBPA CREBBP ETV6 FLT3 JAK2
9 embryo MP:0005380 10.27 CREBBP ETV6 JAK2 KIT KMT2A KRAS
10 neoplasm MP:0002006 10.22 CEBPA CREBBP ETV6 FLT3 JAK2 KIT
11 integument MP:0010771 10.19 CEBPA CREBBP CSF3 ETV6 JAK2 KIT
12 liver/biliary system MP:0005370 10.18 CEBPA CREBBP JAK2 KIT KMT2A KRAS
13 no phenotypic analysis MP:0003012 10.15 AFF1 CEBPA ETV6 FLT3 KIT KMT2A
14 normal MP:0002873 10.13 CEBPA CREBBP DNTT ETV6 JAK2 KIT
15 muscle MP:0005369 10.03 CEBPA CREBBP KIT KMT2A KRAS PAX5
16 reproductive system MP:0005389 9.81 AFF1 CEBPA JAK2 KIT KMT2A KRAS
17 renal/urinary system MP:0005367 9.8 CEBPA CSF3 KIT KMT2A KRAS TCF3
18 respiratory system MP:0005388 9.5 CEBPA CREBBP JAK2 KIT KRAS RUNX1
19 skeleton MP:0005390 9.32 CREBBP FLT3 JAK2 KIT KMT2A KRAS

Drugs & Therapeutics for Acute Leukemia

Drugs for Acute Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 424)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 4 57-22-7, 2068-78-2 5978
2
Mercaptopurine Approved Phase 4 50-44-2 667490
3
Daunorubicin Approved Phase 4 20830-81-3 30323
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5
Arsenic trioxide Approved, Investigational Phase 4 1327-53-3 518740
6
Micafungin Approved, Investigational Phase 4 235114-32-6 477468 3081921
7
Cefepime Approved, Investigational Phase 4 88040-23-7 5479537
8
Ceftazidime Approved Phase 4 72558-82-8, 78439-06-2 5481173
9
Rasburicase Approved, Investigational Phase 4 134774-45-1
10
Lenograstim Approved, Investigational Phase 4 135968-09-1
11
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965 14956
12
Sargramostim Approved, Investigational Phase 4 83869-56-1, 123774-72-1
13
Uric acid Investigational Phase 4 69-93-2 1175
14 Hormones Phase 4
15 Hormone Antagonists Phase 4
16 glucocorticoids Phase 4
17 Anti-Inflammatory Agents Phase 4
18 Tubulin Modulators Phase 4
19 Antimitotic Agents Phase 4
20 Mitogens Phase 4
21 Amebicides Phase 4
22 Antiparasitic Agents Phase 4
23 Antiprotozoal Agents Phase 4
24 Liposomal amphotericin B Phase 4
25 Adjuvants, Immunologic Phase 4
26
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
27
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
28
Oprelvekin Approved, Investigational Phase 2, Phase 3 145941-26-0
29
Lorazepam Approved Phase 3 846-49-1 3958
30
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
31
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
32
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
33
Clove Approved Phase 2, Phase 3 84961-50-2
34
Dalteparin Approved Phase 3 9005-49-6
35
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
36
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
37
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
38
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
39
Ofloxacin Approved Phase 3 82419-36-1 4583
40
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
41
Pentostatin Approved, Investigational Phase 3 53910-25-1 439693 40926
42
Chlorambucil Approved Phase 3 305-03-3 2708
43
Adenosine Approved, Investigational Phase 3 58-61-7 60961
44
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
45
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
46
Vinblastine Approved Phase 3 865-21-4 241903 13342
47
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
48
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
49
Acetylcysteine Approved, Investigational Phase 3 616-91-1 12035
50
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314

Interventional clinical trials:

(show top 50) (show all 922)
# Name Status NCT ID Phase Drugs
1 Treatment Plan for Hematologic Malignancies Using Intravenous Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide to Examine Results, Success and Side Effects of Treatment With Chemotherapy Only, as a Preparative Therapy for Patients With Cord Blood Transplants Unknown status NCT01339988 Phase 4 Busulfan/Cyclophosphamide
2 Treatment of Relapsed Acute Promyelocytic Leukemia With Arsenic Trioxide (Phase IV Study) Unknown status NCT00196768 Phase 4 Arsenic trioxide;Trisenox
3 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
4 A Phase IV Study of Corticosteroids As Prophylaxis for Infusion-Related Adverse Events to Mylotarg® in Patients With Acute Myelogenous Leukemia (AML) Completed NCT00304447 Phase 4 Mylotarg
5 Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever in Pediatric Acute Leukemia: Review of Temperature and Absolute Neutrophil Completed NCT04187755 Phase 4 Ceftazidime Injection;Cefepime Injection
6 AmBisome® in Combination With Caspofungin Versus AmBisome® High Dose Regimen for the Treatment of Invasive Aspergillosis in Immunocompromized Patients: Randomized Pilot Study. Completed NCT00334412 Phase 4 Ambisome;caspofungin
7 APL-R2007: Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Completed NCT00504764 Phase 4 Arsenic Trioxide;ATRA
8 Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Completed NCT02036489 Phase 4 Vincristine;Daunorubicin;Prednisone;L-asparaginase;Ciclophosphamide;Metotrexate;ARA-C;Hidrocortisone;Mercaptopurine;VP-16;Dexametasone
9 An Open-label, Single-arm, Multi-center Study to Evaluate the Efficacy and Safety of Rasburicase (Fasturtec) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin¿s Lymphoma and Acute Leukemia Recruiting NCT04349306 Phase 4 RASBURICASE SR29142
10 Treatment With Thrombopoietin Mimetic Plus Immunosuppressive Therapy in Egyptian Patients With Aplastic Anaemia Recruiting NCT03896971 Phase 4 Combination of thrombopoietin mimetic and cyclosporin A
11 Safety and Efficacy Study of Busulfan/FLAG Conditioning Regimen in Patients With Relapsed/Refractory Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation Not yet recruiting NCT02784561 Phase 4 Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd);Cytarabine(Actavis Italy S.p.A);Fludarabine (Bayer);granulocyte colony-stimulating factor (KirinKunpeng);rabbit ATG(Sanofi/Genzyme)
12 A Randomized,Open,Multicenter and Prospective Study of the Optimized Dose of Anti-Thymoglobuline in Haploidentical Allogeneic Stem Cell Transplantation Not yet recruiting NCT03190733 Phase 4 ATG
13 ProphyALL - Pilot Study on Safety of Four Weekly Administrations of 7 mg/kg of Liposomal Amphotericin B (AmBisome®) in Antifungal Primary Prophylaxis Treatment of Elderly Patients With Acute Lymphoblastic Leukemia Undergoing Induction Chemotherapy Within the GMALL-Elderly Protocol Terminated NCT00386997 Phase 4 liposomal amphotericin B (AmBisome®)
14 Subcutaneous (SC) vs. Intravenous (IV) Granulocyte Colony Stimulating Factors (G-CSF) for the Treatment of Neutropenia in Hospitalized Haemato-oncological Patients: Randomized Controlled Trial Terminated NCT01222819 Phase 4 filgrastim
15 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
16 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
17 The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood Unknown status NCT00003728 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
18 Oral Voriconazole vs IV Low Dose Amphotericin B for Primary Antifungal Prophylaxis in Pediatric Acute Leukemia Induction:A Prospective, Randomized, Clinical Trial. Unknown status NCT00624143 Phase 3 ORAL VORICONAZOLE and IV Amphotericin B
19 Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Unknown status NCT01809392 Phase 2, Phase 3 decitabine
20 Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia in Patients With Acute Leukemia Receiving Chemotherapy Unknown status NCT02241031 Phase 2, Phase 3 thrombopoietin (TPO) and interleukin-11
21 The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years Unknown status NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
22 A Prospective, Multicenter Randomized Study Comparing Single Versus Double Umbilical Cord Blood Transplantation in Children and Young Adults (<35 Years) With Acute Leukemia Remission Unknown status NCT01067300 Phase 3
23 Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies Unknown status NCT00619879 Phase 3 Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients;Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies
24 A Randomized Trial of Thymoglobulin to Prevent Chronic Graft Versus Host Disease in Patients Undergoing Hematopoietic Progenitor Cell Transplantation (HPCT) From Unrelated Donors Unknown status NCT01217723 Phase 3
25 Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation Unknown status NCT01800643 Phase 2, Phase 3
26 A RANDOMIZED TRIAL OF UNMODIFIED VERSUS T-CELL DEPLETED ALLOGENEIC HLA-IDENTICAL BONE MARROW TRANSPLANTATION FOR THE TREATMENT OF ACUTE LEUKEMIAS Completed NCT00002534 Phase 3 cyclophosphamide;cytarabine;methylprednisolone;thiotepa
27 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
28 Clofarabine, Cyclophosfamide, And Etoposide For The Treatment Of Relapsed Or Resistant Acute Leukemia In Pediatric Patients Completed NCT01385891 Phase 2, Phase 3 Clofarabine VP 16 ciclophospahamide
29 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
30 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
31 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
32 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
33 The Unrelated Donor Marrow Transplantation Trial Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
34 A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT) Completed NCT01371656 Phase 3 levofloxacin
35 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
36 A Phase III, Randomized, Multicentre Trial Comparing Allogeneic Filgrastim Mobilised Peripheral Blood Progenitor Cell Transplantation (PBPCT) With Allogeneic Bone Marrow Transplantation (BMT) in Patients With Acute Leukemia, Chronic Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT01020175 Phase 3
37 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
38 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
39 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
40 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
41 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
42 Minimal Residual Disease-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allogenetic Hematopoietic Stem Cell Transplantation Completed NCT02673008 Phase 2, Phase 3
43 A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission Completed NCT00093470 Phase 3 Tipifarnib
44 Prophylaxis of Chronic Graft-versus-host Disease (cGvHD) With or Without Anti-T-lymphocyte-globulin (ATG Fresenius) Prior Allogeneic Peripheral Stem Cell Transplantation From HLA-identical Siblings After Myeloablative Conditioning in Patients With Acute Leukemia: A Randomized Phase III-study Completed NCT00678275 Phase 3 ATG FRESENIUS (Anti-Lymphocyte-Globulin);ATG FRESENIUS (Anti-Lymphocyte-Globulin)
45 A Randomized Study of Two Doses Gemtuzumab Ozogamicin vs. A Two-year Maintenance With Atra Plus Chemotherapy as Post-consolidation Treatment for Intermediate and High-risk Adult Patients With Acute Promyelocytic Leukemia (Apl) Completed NCT00962767 Phase 3 gemtuzumab ozogamicin;ATRA plus 6-MP and MTX
46 Phase III Study of MDR Modulation With PSC-833 (NSC #648265) Followed by Immunotherapy With rIL-2 (NSC #373364) vs. No Further Therapy in Previously Untreated Patients With AML &gt;60 Years Completed NCT00003190 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar
47 A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia Completed NCT00046683 Phase 3 alemtuzumab
48 Phase III Randomized Study of Induction Chemotherapy With or Without MDR-Modulation With PSC-833 (NSC # 648265, IND # 41121) Followed by Cytogenetic Risk-Adapted Intensification Therapy Followed by Immunotherapy With rIL-2 (NSC # 373364, IND # 1969) vs. Observation in Previously Untreated Patients With AML &lt; 60 Years Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
49 Phase 3 Study of US-ATG-F to Prevent Moderate to Severe Chronic GVHD in Adult Acute Myeloid Leukemia, Acute Lymphoid Leukemia, and Myelodysplastic Syndrome Patients After Allogeneic Stem Cell Transplantation From Unrelated Donors Completed NCT01295710 Phase 3
50 Detection of Minimal Residual Disease in Newly Diagnosed Patients With Leukemia and Those Who Undergo a Bone Marrow Transplant Using the Wilms Tumor Suppressor Gene (WT1) as a Marker By RT-PCR Completed NCT00179829 Phase 2, Phase 3

Search NIH Clinical Center for Acute Leukemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Acute Leukemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Acute Leukemia:
Promostem, mesenchymal stem cells for treatment of graft-versus-host disease

Genetic Tests for Acute Leukemia

Genetic tests related to Acute Leukemia:

# Genetic test Affiliating Genes
1 Acute Leukemia 29

Anatomical Context for Acute Leukemia

MalaCards organs/tissues related to Acute Leukemia:

40
Myeloid, Bone, Bone Marrow, T Cells, B Cells, Testes, Monocytes

Publications for Acute Leukemia

Articles related to Acute Leukemia:

(show top 50) (show all 17111)
# Title Authors PMID Year
1
Bench to bedside targeting of FLT3 in acute leukemia. 54 61
20370649 2010
2
Targeting CREB for cancer therapy: friend or foe. 54 61
20370681 2010
3
A role for PKR in hematologic malignancies. 54 61
20232306 2010
4
Clinical correlation of circulating heat shock protein 70 in acute leukemia. 61 54
19800118 2010
5
Complex and cryptic chromosomal rearrangements involving the MLL gene in acute leukemia: a study of 7 patients and review of the literature. 54 61
20206559 2010
6
RUNX1/core binding factor A2 regulates platelet 12-lipoxygenase gene (ALOX12): studies in human RUNX1 haplodeficiency. 54 61
20181616 2010
7
[Expression of CREB/Bcl-2 in bone marrow mononuclear cells of children with acute leukemia]. 61 54
20350424 2010
8
Functional characterization of high levels of meningioma 1 as collaborating oncogene in acute leukemia. 54 61
20072157 2010
9
The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0. 54 61
20111912 2010
10
Retroviral insertional mutagenesis identifies Zeb2 activation as a novel leukemogenic collaborating event in CALM-AF10 transgenic mice. 54 61
20007546 2010
11
Droplet-based gene expression analysis using a device with magnetic force-based-droplet-handling system. 61 54
20129107 2010
12
Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia. 54 61
20306249 2010
13
[FLT3 gene mutation and its prognostic implication in patients with acute leukemia.]. 61 54
20302766 2010
14
Cytochemically myeloperoxidase positive childhood acute leukemia with lymphoblastic morphology treated as lymphoblastic leukemia. 61 54
19935430 2010
15
PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells. 54 61
20145726 2010
16
[Clinical significance of detecting serum erythropoietin in patients with leukemia]. 61 54
19923094 2009
17
Discrepant immunophenotypic characteristics between the lymph node and bone marrow in two mixed-phenotype acute leukemia patients. 61 54
19893347 2009
18
PKR activity is required for acute leukemic cell maintenance and growth: a role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation. 61 54
19507191 2009
19
Rearrangements of the MLL gene are influenced by DNA secondary structure, potentially mediated by topoisomerase II binding. 54 61
19530238 2009
20
Outcomes of CAG regimen for refractory biphenotypic acute leukemia patients. 54 61
19848320 2009
21
Wilms' tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia. 61 54
19811333 2009
22
[Studies on the mutation and polymorphism of the TPMT gene in Chinese children with acute leukemia]. 61 54
20017316 2009
23
New insights to the MLL recombinome of acute leukemias. 54 61
19262598 2009
24
ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells. 54 61
19635183 2009
25
GATA-1 and GATA-2 binding to 3' enhancer of WT1 gene is essential for its transcription in acute leukemia and solid tumor cell lines. 61 54
19212333 2009
26
Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia. 61 54
19250671 2009
27
Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3. 54 61
19411632 2009
28
Clinical and biological characteristics of adult biphenotypic acute leukemia in comparison with that of acute myeloid leukemia and acute lymphoblastic leukemia: a case series of a Chinese population. 61 54
19454497 2009
29
Detection of myeloperoxidase activity in primary leukemic cells by an enhanced chemiluminescent assay for differentiation between acute lymphoblastic and non-lymphoblastic leukemia. 54 61
19298796 2009
30
Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. 61 54
19279403 2009
31
High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. 61 54
19357396 2009
32
[IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia]. 61 54
19379589 2009
33
[Myeloproliferative diseases caused by JAK2 mutation]. 61 54
19489438 2009
34
Overexpression of an isoform of AML1 in acute leukemia and its potential role in leukemogenesis. 54 61
19151769 2009
35
Transforming activity of AML1-ETO is independent of CBFbeta and ETO interaction but requires formation of homo-oligomeric complexes. 54 61
19202074 2009
36
Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. 54 61
19036706 2009
37
A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene. 54 61
18948576 2009
38
Acute leukemia of ambiguous lineage, biphenotype, without CD34, TdT or TCR-rearrangement. 61 54
19687594 2009
39
RAS, FLT3, and C-KIT mutations in immunophenotyped canine leukemias. 54 61
18977066 2009
40
Expression of lineage markers using real-time quantitative polymerase chain reaction (RT-qPCR) in normal and in leukemia bone marrow. 61 54
19327122 2009
41
Maternal acute lymphoctic leukemia with rearrangement of the mixed lineage leukemia gene occurring during pregnancy. 54 61
20139053 2009
42
New thrombopoietic growth factors. 61 54
19778863 2009
43
The role of myeloid growth factors in acute leukemia. 61 54
19176208 2009
44
Chromosomal rearrangements leading to MLL gene fusions: clinical and biological aspects. 61 54
19074864 2008
45
Clinical relevance of FLT3 gene abnormalities in Brazilian patients with infant leukemia. 54 61
19052976 2008
46
[Expression of erythropoietin receptor in leukemia cells and relation of erythropoietin level with leukemic anemia]. 61 54
19099624 2008
47
Assessment of P-gp and MRP1 activities using MultiDrugQuant Assay Kit: a preliminary study of correlation between protein expressions and its functional activities in newly diagnosed acute leukaemia patients. 61 54
19291917 2008
48
[Expression of SALL4 and BMI-1 mRNA in acute leukemia]. 54 61
19099625 2008
49
Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK. 61 54
18948750 2008
50
[Expression of cyclin A in childhood acute leukemia and its significance]. 54 61
19176011 2008

Variations for Acute Leukemia

Expression for Acute Leukemia

Search GEO for disease gene expression data for Acute Leukemia.

Pathways for Acute Leukemia

GO Terms for Acute Leukemia

Cellular components related to Acute Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.9 WT1 TCF3 RUNX1 PAX5 MLLT3 KMT2A
2 cytosol GO:0005829 9.77 WT1 STMN1 PAX5 MTHFR MLLT3 KRAS
3 nuclear chromatin GO:0000790 9.17 TCF3 RUNX1 PAX5 ETV6 DNTT CREBBP

Biological processes related to Acute Leukemia according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 10.04 WT1 RUNX1 MLLT3 KIT ETV6 CEBPA
2 positive regulation of cell proliferation GO:0008284 9.98 KRAS KIT JAK2 FLT3 CSF3
3 negative regulation of transcription by RNA polymerase II GO:0000122 9.95 WT1 TCF3 RUNX1 PAX5 ETV6 CREBBP
4 transcription by RNA polymerase II GO:0006366 9.89 PAX5 MLLT3 KMT2A CEBPA
5 MAPK cascade GO:0000165 9.88 KRAS KIT JAK2 FLT3
6 positive regulation of transcription by RNA polymerase II GO:0045944 9.81 WT1 TCF3 RUNX1 PAX5 KMT2A ETV6
7 positive regulation of transcription, DNA-templated GO:0045893 9.8 WT1 TCF3 RUNX1 MLLT3 KMT2A CREBBP
8 B cell differentiation GO:0030183 9.7 TCF3 KIT FLT3
9 hemopoiesis GO:0030097 9.69 RUNX1 KIT FLT3
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.67 KIT JAK2 FLT3
11 positive regulation of DNA-binding transcription factor activity GO:0051091 9.67 TCF3 KIT JAK2 CSF3
12 regulation of hematopoietic stem cell differentiation GO:1902036 9.65 TCF3 RUNX1 KMT2A
13 regulation of transcription, DNA-templated GO:0006355 9.65 WT1 TCF3 RUNX1 PAX5 MLLT3 KMT2A
14 positive regulation of MAP kinase activity GO:0043406 9.63 KRAS KIT FLT3
15 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.62 KIT JAK2 FLT3 CSF3
16 embryonic hemopoiesis GO:0035162 9.61 KMT2A KIT
17 hematopoietic stem cell proliferation GO:0071425 9.6 RUNX1 ETV6
18 regulation of B cell receptor signaling pathway GO:0050855 9.56 RUNX1 PAX5
19 regulation of myeloid cell differentiation GO:0045637 9.55 RUNX1 CREBBP
20 granulocyte differentiation GO:0030851 9.54 CSF3 CEBPA
21 myeloid progenitor cell differentiation GO:0002318 9.43 KIT FLT3
22 cytokine-mediated signaling pathway GO:0019221 9.1 KRAS KIT JAK2 FLT3 CSF3 CEBPA

Molecular functions related to Acute Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.91 WT1 TCF3 RUNX1 PAX5 MLLT3 KMT2A
2 transcription regulatory region sequence-specific DNA binding GO:0000976 9.67 WT1 RUNX1 KMT2A CEBPA
3 transcription regulatory region DNA binding GO:0044212 9.62 WT1 RUNX1 KMT2A CEBPA
4 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.55 WT1 RUNX1 PAX5 ETV6 CEBPA
5 DNA-binding transcription factor activity GO:0003700 9.5 WT1 TCF3 RUNX1 PAX5 ETV6 CEBPA
6 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.23 WT1 TCF3 RUNX1 PAX5 MLLT3 KMT2A

Sources for Acute Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....